UY28057A1 - Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos - Google Patents

Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos

Info

Publication number
UY28057A1
UY28057A1 UY28057A UY28057A UY28057A1 UY 28057 A1 UY28057 A1 UY 28057A1 UY 28057 A UY28057 A UY 28057A UY 28057 A UY28057 A UY 28057A UY 28057 A1 UY28057 A1 UY 28057A1
Authority
UY
Uruguay
Prior art keywords
formulation
hydrophobic
dosage
pharmacos
biodisponibility
Prior art date
Application number
UY28057A
Other languages
English (en)
Inventor
Patrick S L Wong
Liang Dong
Ruiping Zhao
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of UY28057A1 publication Critical patent/UY28057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provee una formulación del fármaco y una forma de dosificación. La formulación del fármaco cumple la función de incrementar la biodisponibilidad de los fármacos hidrófobos administrados al tracto gastrointestinal ("tracto GI") de un sujeto determinado. La forma de dosificación, puede formarse utilizando varios materiales diferentes y puede configurarse para administrar la formulación del fármaco de la presente invención al tracto GI de un sujeto utilizando cualquier mecanismo adecuado.
UY28057A 2002-10-31 2003-10-31 Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos UY28057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42318402P 2002-10-31 2002-10-31

Publications (1)

Publication Number Publication Date
UY28057A1 true UY28057A1 (es) 2003-12-31

Family

ID=32312618

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28057A UY28057A1 (es) 2002-10-31 2003-10-31 Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos

Country Status (11)

Country Link
US (1) US20040142040A1 (es)
EP (1) EP1556000A1 (es)
JP (1) JP2006507309A (es)
KR (1) KR20050083875A (es)
CN (1) CN1728982A (es)
AR (1) AR041745A1 (es)
AU (1) AU2003291667A1 (es)
CA (1) CA2504031A1 (es)
TW (1) TW200423968A (es)
UY (1) UY28057A1 (es)
WO (1) WO2004041246A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230885A1 (en) * 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20060047025A1 (en) * 2004-06-29 2006-03-02 Matthew Piazza Viscous materials and method for producing
EP1791520A2 (en) * 2004-08-19 2007-06-06 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
KR101327649B1 (ko) * 2005-03-31 2013-11-12 산토리 홀딩스 가부시키가이샤 리그난류 화합물 함유 수중 유적형 에멀션 및 그것을함유하는 조성물
KR100682531B1 (ko) 2005-04-06 2007-02-15 유효경 양쪽성 계면활성제와 폴리올을 함유하는 가용화용나노조성물
US20070077309A1 (en) * 2005-09-30 2007-04-05 Wong Patrick S Banded controlled release nanoparticle active agent formulation dosage forms and methods
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
WO2008044550A1 (fr) * 2006-10-04 2008-04-17 Suntory Limited Émulsion de type huile/eau/huile contenant un composé de lignane, et composition la contenant
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
IT1393245B1 (it) * 2008-07-24 2012-04-12 Universita' Degli Studi Di Milano Forme farmaceutiche per il rilascio tempo-specifico di farmaci
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US9431262B2 (en) 2014-03-14 2016-08-30 Fujikoshi Machinery Corp. Method for polishing work and work polishing apparatus
AU2015341479B2 (en) * 2014-11-04 2020-11-26 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
GB2541387A (en) * 2015-08-14 2017-02-22 Res Center Pharmaceutical Eng Gmbh Self-emulsifying Nanosuspensions as Drug Delivery Systems (SENDDS)
PL428779A1 (pl) * 2019-01-31 2020-08-10 Gdański Uniwersytet Medyczny Kompozycja farmaceutyczna w postaci ciekłej zawierająca jako substancję aktywną substancję leczniczą nietrwałą w środowisku wodnym

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534280A (en) * 1895-02-19 Hose-leak stop or jacket
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5578642A (en) * 1994-08-17 1996-11-26 Henkel Corporation Self-emulsifying and/or emollient agents
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
AU692255B2 (en) * 1995-04-24 1998-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
AU724635B2 (en) * 1997-07-01 2000-09-28 Pfizer Products Inc. Gelatine encapsulated solution dosage forms of sertraline
JP4761093B2 (ja) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6183466B1 (en) * 1998-08-21 2001-02-06 Alza Corporation Dosage form comprising a capsule
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6221391B1 (en) * 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
IL143580A0 (en) * 1998-12-11 2002-04-21 Pharmasolutions Inc Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
CN1161101C (zh) * 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
AU7709901A (en) * 2000-07-24 2002-02-05 Upjohn Co Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
ATE370744T1 (de) * 2000-09-18 2007-09-15 Rpg Life Sciences Ltd Selbstemulgierende formulierung mit erhöhter bioverfügbarkeit und immunsupprimierender wirkung
WO2003053400A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
WO2004041246A1 (en) 2004-05-21
TW200423968A (en) 2004-11-16
KR20050083875A (ko) 2005-08-26
CN1728982A (zh) 2006-02-01
AR041745A1 (es) 2005-05-26
JP2006507309A (ja) 2006-03-02
AU2003291667A1 (en) 2004-06-07
CA2504031A1 (en) 2004-05-21
US20040142040A1 (en) 2004-07-22
EP1556000A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
UY28057A1 (es) Formulacion y forma de dosificacion que provee mayor biodisponibilidad de los farmacos hidrófobos
CY1118936T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για την αγωγη ή την προληψη νοσου σχετιζομενης με οξαλικο
CY1109122T1 (el) Μηχανισμος εμφανισης δοσολογιας για μια συσκευη χορηγησης φαρμακου
BRPI0519171A2 (pt) dispositivo de administraÇço de medicamento oftÁlmico
DK1957110T3 (da) Fremgangsmåde til fremstilling af tygbare doseringsformer til lægemiddeladministration og produkter dermed
NO20045656L (no) Oftalmologisk anvendelse av roflumilast for behandlingen av oyesykdommer
BRPI0406486A (pt) Dispositivo de administração para medicamento fluido
AR084816A1 (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
ATE277594T1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
ATE474559T1 (de) Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
PA8564001A1 (es) Aza-arilpiperazinas
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
ATE486611T1 (de) Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
DE60326709D1 (de) Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
EA201101706A1 (ru) Лекарственное средство на основе дииндолилметана(dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
AR048342A1 (es) FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)
ATE439832T1 (de) Feste pharmazeutische arzneimittelformulierung enthaltend diacerein und meloxicam
ATE366105T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
DE60205905D1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
ATE454891T1 (de) Geschmacksstoffhaltige arzneimittelformulierungen mit verbesserten pharmazeutischen eigenschaften
EA200401097A1 (ru) Лекарственная форма с регулируемым высвобождением активного ингредиента